|
Jun 19
|
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
|
|
Jun 19
|
Ascidian and Roche to develop RNA therapies for neurological diseases
|
|
Jun 18
|
Roche gains 501(k) clearance for digital pathology solution for diagnostic use
|
|
Jun 18
|
Roche partners with RNA editing biotech Ascidian
|
|
May 10
|
Q1 2024 Lineage Cell Therapeutics Inc Earnings Call
|
|
May 9
|
Phanes Therapeutics signs clinical supply agreement with Roche
|
|
May 8
|
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Q1 2024 Halozyme Therapeutics Inc Earnings Call
|
|
Jan 16
|
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
|
|
Jan 16
|
Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU
|
|
Jan 16
|
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
|
|
Jan 12
|
The Zacks Analyst Blog Highlights Roche, Netflix, NIKE, Uber, Technologies and Prologis
|
|
Jan 12
|
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
|
|
Jan 11
|
Top Research Reports for Roche, Netflix & NIKE
|
|
Jan 11
|
Renewables grew rapidly in 2023, but must grow faster still to meet climate change target, IEA says
|
|
Jan 10
|
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
|
|
Jan 10
|
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
|
|
Jan 10
|
Swiss Pharma Giants Who Missed Boat on Obesity Fight to Stay Relevant
|
|
Jan 9
|
How Roche aims to change the 'standard of care'
|
|
Jan 9
|
Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
|